At a glance
- Originator Amgen
- Developer Amgen; NantPharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastric cancer; Oesophageal cancer; Sarcoma; Solid tumours
Most Recent Events
- 13 Dec 2022 NantPharma terminated its phase II trial in Late-stage disease, Metastatic disease, In adolescents, In adults, In the elderly, Inoperable/Unresectable) in USA (PO) due to lack of therapeutic efficacy (NCT03132155)
- 29 Nov 2022 Phase II development is ongoing for Sarcoma (Late-stage disease, Metastatic disease, In adolescents, In adults, In the elderly, Inoperable/Unresectable) in USA (PO) (NCT03132155)
- 18 Sep 2020 Phase II development is ongoing for Sarcoma (Late-stage disease, Metastatic disease, In adolescents, In adults, In the elderly, Inoperable/Unresectable) in USA (PO) (NCT03132155)